论文部分内容阅读
目的探讨CAG方案治疗骨髓增生异常综合征-难治性贫血伴原始细胞增多(MDS-RAEB)的近期疗效。方法9例患者使用CAG方案:阿糖胞苷(Ara-C)25mg/m2,静脉滴注,第1￣14天;阿柔比星7mg/m2,静脉滴注,第1￣8天,GM-CSF150μg/d,皮下注射,第1￣14天,两个疗程后做评定。结果9例患者经CAG治疗,5例获得完全缓解(CR),CR率55.6%,2例获得部分缓解(PR),PR率22.2%,总的有效率88.9%,毒副反应主要为骨髓抑制,白细胞减少。结论CAG方案治疗MDS-RAEB行之有效,且毒副反应较轻。
Objective To investigate the short-term curative effect of CAG regimen in treatment of myelodysplastic syndrome-refractory anemia with proliferative myelocytosis (MDS-RAEB). Methods Nine patients underwent CAG regimen: Cytarabine (Ara-C) 25mg / m2, intravenous drip, 1st to 14th days, 7mg / m2 of amrubicin, intravenous drip, 1st to 8th day, GM - CSF150μg / d, subcutaneous injection, the first ~ 14 days, to be assessed after two courses. Results Nine patients were treated with CAG, 5 patients achieved complete remission (CR), CR rate was 55.6%, partial response (PR) was achieved in 2 patients, PR rate was 22.2% and total effective rate was 88.9%. The main side effects were myelosuppression ,Leukopenia. Conclusion CAG regimen is effective in treating MDS-RAEB with mild toxicity.